Literature DB >> 15959620

Camurati-Engelmann disease (progressive diaphyseal dysplasia) in a Moroccan family.

S Simsek1, K Janssens, M L Kwee, W Van Hul, J Veenstra, J C Netelenbos.   

Abstract

We report on a 46-year-old mother of Moroccan origin, suffering mainly from painful, swollen legs, and her 26-year-old son who had experienced intense pain in his legs, without fever, for approximately 3 years. They did not have dysmorphic features or abnormal gaits. Radiographic studies of the mother revealed diaphyseal sclerosis of the tibia and spondylosis of the thoracal and lumbar vertebrae. The son had sclerosis of the diaphyses of the metacarpalia of the left hand, the femur and the fibula. The other parts of the skeleton were normal. Several osteosclerotic/hyperostotic disorders, such as melorheostosis (present mostly in sporadic cases and affecting lower extremities) and van Buchem's disease (autosomal recessive and commonly affecting the mandible) were considered as a diagnosis in the proposita. However, similar symptoms in the son of the proposita suggested an autosomal dominant inheritance pattern. This brought us to the diagnosis of progressive diaphyseal dysplasia (PDD) or Camurati-Engelmann disease (CED), an autosomal dominant disorder characterized by limb pain, reduced muscle mass, weakness, a waddling gait, progressive periosteal and endosteal sclerosis of the diaphyses of the long bones and sclerosis of the skull base. Mutations in the transforming growth factor (TGF)-beta1 gene on chromosome 19q13.1 have been reported to cause this disorder. The diagnosis of PDD/CED in this family was confirmed at the molecular level by detection of a C-to-T transition at position 466, leading to an arginine-to-cysteine amino acid change (position 156) in exon 2 of the transforming growth factor-beta1 (TGFB1) gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15959620     DOI: 10.1007/s00198-005-1896-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  8 in total

1.  Evidence for locus heterogeneity in the Camurati-Engelmann (DPD1) Syndrome.

Authors:  J T Hecht; S H Blanton; S Broussard; A Scott; C Rhoades Hall; J M Milunsky
Journal:  Clin Genet       Date:  2001-03       Impact factor: 4.438

2.  Domain-specific mutations of a transforming growth factor (TGF)-beta 1 latency-associated peptide cause Camurati-Engelmann disease because of the formation of a constitutively active form of TGF-beta 1.

Authors:  T Saito; A Kinoshita; Y Makita; K Wakui; K Honke; N Niikawa; N Taniguchi
Journal:  J Biol Chem       Date:  2001-02-13       Impact factor: 5.157

3.  Case for Diagnosis.

Authors:  E A Cockayne
Journal:  Proc R Soc Med       Date:  1920

Review 4.  Sclerosing bone dysplasias: genetic and radioclinical features.

Authors:  F M Vanhoenacker; L H De Beuckeleer; W Van Hul; W Balemans; G J Tan; S C Hill; A M De Schepper
Journal:  Eur Radiol       Date:  2000       Impact factor: 5.315

5.  Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease.

Authors:  A Kinoshita; T Saito; H Tomita; Y Makita; K Yoshida; M Ghadami; K Yamada; S Kondo; S Ikegawa; G Nishimura; Y Fukushima; T Nakagomi; H Saito; T Sugimoto; M Kamegaya; K Hisa; J C Murray; N Taniguchi; N Niikawa; K Yoshiura
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

6.  Phenotypic variability at the TGF-beta1 locus in Camurati-Engelmann disease.

Authors:  B Campos-Xavier; J M Saraiva; R Savarirayan; A Verloes; J Feingold; L Faivre; A Munnich; M Le Merrer; V Cormier-Daire
Journal:  Hum Genet       Date:  2001-11-09       Impact factor: 4.132

7.  Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease.

Authors:  K Janssens; R Gershoni-Baruch; N Guañabens; N Migone; S Ralston; M Bonduelle; W Lissens; L Van Maldergem; F Vanhoenacker; L Verbruggen; W Van Hul
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

8.  Transforming growth factor-beta 1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein.

Authors:  Katrien Janssens; Peter ten Dijke; Stuart H Ralston; Carsten Bergmann; Wim Van Hul
Journal:  J Biol Chem       Date:  2002-12-18       Impact factor: 5.157

  8 in total
  7 in total

1.  A significant improvement in lower limb pain after treatment with alendronate in two cases of Camurati-Engelmann disease.

Authors:  Kousuke Iba; Junichi Takada; Hotaka Kamasaki; Takashi Oda; Naoko Hatakeyama; Takuro Wada; Toshihiko Yamashita
Journal:  J Bone Miner Metab       Date:  2008-01-10       Impact factor: 2.626

Review 2.  Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment.

Authors:  K Janssens; F Vanhoenacker; M Bonduelle; L Verbruggen; L Van Maldergem; S Ralston; N Guañabens; N Migone; S Wientroub; M T Divizia; C Bergmann; C Bennett; S Simsek; S Melançon; T Cundy; W Van Hul
Journal:  J Med Genet       Date:  2005-05-13       Impact factor: 6.318

3.  Camurati-Engelmann disease: imaging, clinical features and differential diagnosis.

Authors:  Aldona Bartuseviciene; Arturas Samuilis; Jovitas Skucas
Journal:  Skeletal Radiol       Date:  2009-02-12       Impact factor: 2.199

4.  Camurati-Engelmann disease: unique variant featuring a novel mutation in TGFβ1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand.

Authors:  Michael P Whyte; William G Totty; Deborah V Novack; Xiafang Zhang; Deborah Wenkert; Steven Mumm
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

5.  Orthopedic Manifestations of Type I Camurati-Engelmann Disease.

Authors:  Alisher J Yuldashev; Chang Ho Shin; Yong Sung Kim; Woo Young Jang; Moon Seok Park; Jong Hee Chae; Won Joon Yoo; In Ho Choi; Ok Hwa Kim; Tae-Joon Cho
Journal:  Clin Orthop Surg       Date:  2017-02-13

6.  The first Korean case of Camurati-Engelmann disease (progressive diaphyseal dysplasia) confirmed by TGFB1 gene mutation analysis.

Authors:  Seo-Jin Park; Choon Sik Yoon; Hui-Wan Park; Jong Rak Choi; Jong Shin Chung; Kyung-A Lee
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

7.  Visual and otologic manifestation of Camurati-Engelmann's disease: a case report.

Authors:  Tariq Alam; Muhammad Khurram; Hidayatullah Hamidi; Asif Alam Khan
Journal:  Radiol Case Rep       Date:  2015-10-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.